Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 11/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | GLS | O94925 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3056668 | 0.92 | SCD (0.72) | SCDKDM4ESMN1; SMN2TDP1POLB | |
| SCHEMBL3049002 | 0.91 | SCD (0.73) | SCD | |
| SCHEMBL13137814 | 0.88 | SCD (0.55) | SCDKDM4ESMN1; SMN2TDP1POLB | |
| SCHEMBL3045392 | 0.84 | SCD (0.84) | SCDKDM4ESMN1; SMN2TDP1POLB | |
| SCHEMBL13137914 | 0.84 | SCD (0.55) | SCDKDM4ESMN1; SMN2TDP1POLB | |
| SCHEMBL3045565 | 0.84 | SCD (0.61) | SCDKDM4ESMN1; SMN2TDP1POLB | |
| SCHEMBL3046898 | 0.83 | SCD (0.69) | SCDCHRM4 | |
| SCHEMBL3040175 | 0.82 | SCD (0.62) | SCDKDM4ESMN1; SMN2TDP1POLB | |
| SCHEMBL3043064 | 0.82 | SCD (0.65) | SCDKDM4ESMN1; SMN2TDP1POLB | |
| SCHEMBL13137917 | 0.82 | SCD (0.52) | SCDKDM4ESMN1; SMN2TDP1CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9358250-B2 | Methods of using SCD1 antagonists | GENENTECH, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-8258160-B2 | SCD1 inhibitors triazole and tetrazole compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| US-8258160-B2 | SCD1 inhibitors triazole and tetrazole compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| US-20100029722-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| US-20100029722-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| EP-2121671-A1 | 2-SUBSTITUTED 5-MEMBERED HETEROCYCLES AS SCD INHIBITORS | Novartis AG (CH) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008074835-A1 | 2-SUBSTITUTED 5-MEMBERED HETEROCYCLES AS SCD INHIBITORS | NOVARTIS AG (CH) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029722-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | SCD 1/4885KDM4E 683/4885SMN1; SMN2 3581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.